|Bid||114.310 x 1000|
|Ask||115.640 x 900|
|Day's Range||114.590 - 115.750|
|52 Week Range||93.010 - 128.460|
|PE Ratio (TTM)||21.84|
|Earnings Date||Aug 6, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||130.00|
KemPharm (KMPH) presents positive top-line results on ADHD candidate KP415, which meets both primary and secondary endpoints in a pivotal study.
RedHill Biopharma (RDHL) announces allowances of two new patents from the United States Patent and Trademark Office and the European Patent Office for its Crohn's disease candidate, RHB-104.
This article is intended for those of you who are at the beginning of your investing journey and looking to gauge the potential return on investment in Taro Pharmaceutical IndustriesRead More...
Taro Pharmaceutical Industries Ltd. announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2018, filed with the Securities and Exchange Commission , is available within the Investor Relations section of Taro’s website at www.taro.com.
NEW YORK, NY / ACCESSWIRE / May 24, 2018 / U.S. markets rebounded modestly on Wednesday, following the release of Fed's minutes of the meeting, which suggest that the central bank will be slightly dovish ...
LONDON, UK / ACCESSWIRE / May 23, 2018 / If you want access to our free research report on Avenue Therapeutics, Inc. (NASDAQ: ATXI), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ATXI as the Company's latest news hit the wire. On May 21, 2018, the Company announced that its first pivotal Phase-3 trial assessing IV tramadol for treatment of patients with moderate to moderately severe postoperative pain following bunionectomy surgery achieved the primary endpoint of a statistically significant improvement in Sum of Pain Intensity Difference over 48 hours (SPID48) compared to placebo. Active-Investors.com is currently working on the research report for Taro Pharmaceutical Industries Ltd (NYSE: TARO), which also belongs to the Healthcare sector as the Company Avenue Therapeutics.
NEW YORK, NY / ACCESSWIRE / May 18, 2018 / Taro Pharmaceutical Industries Ltd. (NYSE: TARO ) will be discussing their earnings results in their Q4 Earnings Call to be held on May 18, 2018 at 8:00 AM Eastern ...
On a per-share basis, the Haifa Bay, Israel-based company said it had net income of $2.17. The drug maker posted revenue of $175.2 million in the period. For the year, the company reported profit of $211.2 ...
Taro Pharmaceutical Industries Ltd. today provided unaudited financial results for the quarter and year ended March 31, 2018.
Taro Pharmaceutical Industries Ltd (NYSE:TARO) delivered a less impressive 9.39% ROE over the past year, compared to the 12.26% return generated by its industry. An investor may attribute an inferiorRead More...
Taro Pharmaceutical Industries Ltd. announced today that it plans to release its financial results for year ended March 31, 2018, on Thursday, May 17, 2018.
Live Oak Bancshares and Taro Pharmaceutical Industries may be trading at prices below their likely values. This suggests that these stocks are undervalued, meaning we can benefit when the stockRead More...
Taro Pharmaceutical Industries Ltd (NYSE:TARO), a pharmaceuticals company based in Israel, received a lot of attention from a substantial price movement on the NYSE in the over the last fewRead More...
MISSISSAUGA, ON, March 29, 2018 /PRNewswire/ - Crescita Therapeutics Inc. (CTX.TO) ("Crescita" or "the Company"), a commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions and diseases and their symptoms, is pleased to announce that the first shipments of Pliaglis have now been received and the product will be launched by our U.S. licensing partner.
Taro Pharmaceutical Industries Ltd (NYSE:TARO) is trading with a trailing P/E of 19.4x, which is lower than the industry average of 22x. While TARO might seem like an attractive stockRead More...